Journal article

Pharmacogenetic polymorphisms and response to escitalopram and venlafaxine over 8 weeks in major depression

Chee Ng, Jerome Sarris, Ajeet Singh, Chad Bousman, Keith Byron, Lai Huat Peh, Deidre Joy Smith, Chay Hoon Tan, Isaac Schweitzer

HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL | WILEY-BLACKWELL | Published : 2013

Abstract

OBJECTIVE: The objective of this study is to investigate the influence of the 5-HTTLPR (serotonin transporter-linked promoter region), cytochrome P450 2C19, and cytochrome P450 2D6 polymorphisms on escitalopram (ESC) and venlafaxine (VEN) responses in major depressive disorder. METHOD: A prospective multi-site study of 106 patients (Caucasian and Han Chinese ethnicities) with major depressive disorder treated with either ESC or VEN was conducted. The 17-item Hamilton Depression scale (HDRS), Clinical Global Impression Scale, and an adverse events scale (UKU) were assessed over 8 weeks, blind to genotype. RESULTS: At the 8-week end point, a significant HDRS reduction for both ESC and VEN occu..

View full abstract

Grants

Awarded by Australian National Health & Medical Research Council fellowship (NHMRC)


Funding Acknowledgements

The authors kindly acknowledge the contribution of the following persons involved in the study: Michael Berk, Woo Kheng Tay, Sou Yen Soon, Trevor Norman, Kerryn Addison, and KC Crowley. This investigator-initiated study was partly supported by an unrestricted research grant from H. Lundbeck A/S (at the site in Australia) and Changi General Hospital (at the site in Singapore). Courier of samples to Australia was facilitated by Quest Laboratories Pte Ltd. ESC and VEN were sourced from H. Lundbeck A/S and Wyeth, respectively. JS is funded by an Australian National Health & Medical Research Council fellowship (NHMRC funding ID 628875).